Digitoxin for heart failure with reduced ejection fraction?
A recent study found that patients taking digitoxin who had heart failure with reduced ejection fraction had a decrease in the composite of death from any cause or hospital admission for worsening heart failure, in the DIGIT-HF study (which apparently is short for the Digitoxin to Improve Outcomes in Patients with Advanced Chronic Heart Failure trial): see chf HFrEF digitoxin helps NEJM2025 in dropbox, or DOI: 10.1056/NEJMoa2415471) Details -- 1212 patients in this double-blind, placebo-controlled trial from 65 sites in Austria, Germany, and Serbia -- patients with chronic heart failure who had a left ventricular ejection fraction of 40% or less and a New York Heart Association (NYHA) functional class of III or IV, or a left ventricular ejection fraction of 30% or less and an NYHA functional class of II, were randomized to receive digitoxin or matching placebo in addition to guideline-directed medical therapy (all patients had received evidence-based th...